Articles tagged with: Pomalidomide
At the 2013 annual meeting of the American Society of Hematology (ASH), which took place in December, there were many oral and poster presentations about Pomalyst, the newest drug approved in the United States and Europe for the treatment of multiple myeloma.
Many of the presentations were about studies of Pomalyst (pomalidomide, Imnovid) and dexamethasone (Decadron) in combination with a third drug, such as Velcade (bortezomib), Kyprolis (carfilzomib), clarithromycin (Biaxin), cyclophosphamide (Cytoxan), or Doxil (doxorubicin liposomal), for relapsed and refractory myeloma. …
More than twenty presentations about studies involving Pomalyst were presented at this year’s meeting of the American Society of Hematology (ASH), which took place last month.
Several of these presentations were about the Phase 3 clinical trial that found Pomalyst (pomalidomide, Imnovid) plus low-dose dexamethasone (Decadron) significantly improved overall survival of relapsed and refractory myeloma patients compared to high-dose dexamethasone alone (see related Beacon news). This is the study that led to the approval of pomalidomide in Europe, where it is marketed under the brand name …
This Monday was the third day of the 2013 American Society of Hematology (ASH) annual meeting, which was held in New Orleans.
More than any other day of the conference, Monday was packed with important myeloma presentations, from 7:00 in the morning until almost 8:00 in the evening.
This ASH update will summarize the oral presentation sessions about treatment-related myeloma studies that were held Monday morning. An ASH update that was published on Wednesday focused on the sessions that were held Monday afternoon and evening.
Monday morning started with …
Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of …
Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.
As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.
Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.
One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.
The myeloma study included in this …